Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, has been approved for the treatment of active lupus nephritis; however, its efficacy and safety in patients with active Systemic Lupus Erythematosus (SLE) remain to be fully established. To address this gap, a clinical study evaluated the therapeutic efficacy and safety profile of obinutuzumab in 303 patients with active systemic lupus erythematosus. The study found that treatment with Obinutuzumab resulted in significantly higher SLE Responder Index 4 (SRI-4) response rates at week 52 compared with placebo (76.7% vs.
53.5%; adjusted difference, 23.1 percentage points). In an additional analysis accounting for nonfatal intercurrent events, response rates were 85.4% in the obinutuzumab group and 68.5% in the placebo group (adjusted difference, 16.8 percentage points). Obinutuzumab…
